The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The coming months will bring key readouts for companies tackling diseases ranging from ALS to dementia to a rare form of blindness. Here's what to expect.
The jam-packed September biotech catalyst calendar is behind us, which means investors are now focused on the stock-moving binary events that will take us to the end of the year.
STAT is here to help. Introducing the Biotech Q4 Scorecard: Ten companies with important clinical trial and FDA milestones
